Nanostics Announces Publication of a ClarityDX Prostate Study Validating New Algorithms with Improved Cancer Prediction that make MRI or DRE Optional

EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...
Kennesaw State University

Researcher uses emerging technologies to improve prostate cancer detection

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
Hosted on MSN

Prostate cancer explained: From antigen tests to treatment options

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane ...
ascopubs.org

Association between prostate specific membrane antigen imaging and initial treatment for prostate cancer among commercial insurance beneficiaries.

Timing and uptake of germline testing in patients with somatic BRCA1/2 pathogenic or likely pathogenic variants in solid tumors: A real-world study from community oncology practices. Identifying ...
The Washington Post

Biden’s cancer renews debate about prostate screenings for older men

Former president Joe Biden’s newly diagnosed prostate cancer, an aggressive form that has spread to his bones, has renewed the debate about who should receive annual screenings for signs of the ...